Pair Name | Isorhamnetin, Doxorubicin | ||
Phytochemical Name | Isorhamnetin (PubChem CID: 5281654 ) | ||
Anticancer drug Name | Doxorubicin (PubChem CID: 31703 ) | ||
Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
Pair Name | Isorhamnetin, Doxorubicin | |||
Disease Info | [ICD-11: 2C60] | Breast cancer | Investigative | |
Biological Phenomena | Induction-->Blockade of cell cycle in G2/M phase | |||
Gene Regulation | Down-regulation | Expression | BCL2 | hsa596 |
Up-regulation | Cleavage | CASP3 | hsa836 | |
Down-regulation | Expression | MTOR | hsa2475 | |
Down-regulation | Expression | PRKAA1 | hsa5562 | |
Down-regulation | Expression | RPS6KB1 | hsa6198 | |
In Vitro Model | NCI-ADR-RES | High grade ovarian serous adenocarcinoma | Homo sapiens (Human) | CVCL_1452 |
In Vivo Model | a total of 0.1 ml of medium and Matrigel suspension containing 8×10⁷ MCF7/ADR cells was prepared for subcutaneous inoculation. | |||
Result | Isorhamnetin induces cell cycle arrest and apoptosis by triggering DNA damage and regulating the AMPK/mTOR/p70S6K signaling pathway in doxorubicin-resistant breast cancer |
No. | Title | Href |
---|---|---|
1 | Isorhamnetin induces cell cycle arrest and apoptosis by triggering DNA damage and regulating the AMPK/mTOR/p70S6K signaling pathway in doxorubicin-resistant breast cancer. Phytomedicine. 2023 Jun;114:154780. doi: 10.1016/j.phymed.2023.154780. | Click |